Precision medicine for cardiovascular disease

摘要: Evidence-based medicine has considerably advanced the treatment of highly prevalent cardiovascular diseases. Its implementation was driven by multicenter interventional trials in and placebo cohorts, propelling numerous biomedical innovations toward standard care. While a uniform can be effective such disease cohorts (“one size fits all”), it neglects genetic phenotypic individuality a single patient his or her disease. Accordingly, a recent observation made that several newer “mega” trials, demanding considerable resources for their execution, showed statistically significant differences outcome, however, with small overall efficacies render clinics unlikely. To overcome this concerning development, new methods individualized are required. Rarer conditions, as distinct cardiomyopathies, may deliver blueprint a paradigm shift: deep precise phenotyping individual patients a multimodal approach development targeted treatments smaller groups many”) even single some”).